UBS AM
DFTX

UBS AM’s Definium Therapeutics DFTX Stock Holding History

UBS AM’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93M Buy
211,183
+208,770
+8,652% +$5.16M ﹤0.01% 1246
2026
Q1 		$45.6K Buy
2,413
+1,519
+170% +$25.8K ﹤0.01% 2975
2025
Q4 		$12K Sell
894
-116,345
-99% -$1.44M ﹤0.01% 2820
2025
Q3 		$1.38M Buy
117,239
+75,110
+178% +$700K ﹤0.01% 1890
2025
Q2 		$273K Sell
42,129
-3,492
-8% -$23K ﹤0.01% 2532
2025
Q1 		$267K Sell
45,621
-39,423
-46% -$282K ﹤0.01% 2561
2024
Q4 		$592K Buy
85,044
+14,691
+21% +$101K ﹤0.01% 2527
2024
Q3 		$400K Sell
70,353
-7,726
-10% -$53.7K ﹤0.01% 2682
2024
Q2 		$563K Buy
+78,079
New +$683K ﹤0.01% 2598
2021
Q3 		– Sell
-10,867
Closed -$567K – 2764
2021
Q2 		$567K Buy
+10,867
New +$570K ﹤0.01% 2488

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

UBS AM's DFTX Position: Q2 2026 in Review

UBS AM increased its Definium Therapeutics (DFTX) stake by 8,652% in Q2 2026, buying an estimated $5.16M and bringing the position to 211,183 shares worth $9.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

UBS AM first reported a position in DFTX in Q2 2021 and has held it in 10 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • UBS AM held 211,183 shares of Definium Therapeutics worth $9.93M as of Q2 2026.
  • UBS AM bought 208,770 Definium Therapeutics shares in Q2 2026, an estimated $5.16M.
  • Definium Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1246 holding.
  • UBS AM first reported a position in Definium Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.